SpiroFind® Test for Lyme Disease
The SpiroFind® immunoassay for diagnosis of active Lyme disease following a tick bite provides a powerful new tool for the detection of early and long-term infections that are difficult to diagnose with today’s methods and are therefore often overlooked or misdiagnosed.
The SpiroFind test measures the intracellular trained immunity to the specific stimulation of monocyte cells with Borrelia, the infective agent causing Lyme disease. The response is elevated when an active Lyme disease after a tick bite is present. The immune response manifests itself through the secretion of cytokines. The primary cytokine which is measured by the SpiroFind test is interleukine 1 beta (IL-1β)
To differentiate the secretion of the IL-1β cytokine from a generally elevated immune reaction, the SpiroFind test measures the amount of cytokine secretion following stimulation of the cells with four different concentrations of Borrelia (multiplicity of infection MOI).
The specificity of the SpiroFind test originates from the stimulation of the immune cells with the Borrelia. A standard mixture of the three most common infective Borrelia strains, b. burgdorferi, b. afzelii and b. garinii is used for the stimulation. In every assay, two unspecific control stimulations are employed; one with an LPS molecule and one with Candida albicans. From analyzing hundreds of patient samples, we can confirm that the test results of those unspecific stimulations do not correlate with the borrelia stimulation, which corroborates the specificity of the SpiroFind test.
In early clinical study results, the SpiroFind test shows a very strong correlation with clinical treatment response. This means, in cases where the SpiroFind test was positive, patients responded to clinical treatment. In cases where the SpiroFind test was negative, patients did not respond to clinical treatment. Further clinical studies are ongoing at the Radboud University Nijmegen Medical Center, Netherlands and the University Clinic of the University of Erlangen, Germany.
Early Disease: The SpiroFind test is able to reliably diagnose an acute Lyme disease prior to any detection of antibodies, preventing a mis-diagnosis.
Long Term Disease: The SpiroFind test typically sorts out an active Lyme disease in patients with long term symptoms.
Contradictory and questionable results with other testing methods: The SpiroFind test is able to give a predictive results that correspond with subsequent treatment response in cases where other testing methods are inconsistent or questionable.
Treatment course follow-up: The SpiroFind test is able to confirm that treatment was successful.
For more information, please read also the SpiroFind FAQ. Patent Pending
SpiroFind® testing service for the detection of Borrelia infections that cause acute and chronic Lyme disease. We test patient blood for a Borrelia specific immune response and deliver the test result. Our first clinical laboratory in Mellrichstadt, Germany serves the EU region.